

Date and Time: **Thursday 23 July 2009**
10:00–16:00

Minutes: Confirmed

Guideline Development Group Meeting 7

Place: Royal College of Physicians
 11 St Andrew's Place
 Regent's Park
 London NW1 4LE

Present: Mike Sury (Consultant Anaesthetist, Chair) (MS)
 Paul Averley (General Dental Practitioner) (PA)
 Peter Crean (Consultant Paediatric Anaesthetist) (PC)
 Nick Croft (Reader and Consultant Paediatric Gastroenterologist) (NC)
 Susan King (Consultant Radiologist) (SK) left at 15.30
 Christina Lioffi (Senior Lecturer in Health Psychology) (CL)
 Heather McLelland (Nurse Consultant, Emergency Care) (HM)
 Neil Morton (Consultant in Paediatric Anaesthesia & Pain Management) (NMo)
 Farrah Pradhan (Patient/Carer Representative) (FP)
 Daniel Wallis (Consultant - A&E Medicine) (DW)
 Ian Bullock (IB)
 Emily Crowe (Senior Research Fellow) (EC), left at 13.00
 Anayo Akunne (Health Economist) (AA)
 Nahara Martinez (Research Fellow) (NMa)
 Kathy De Mott (Research Fellow) (KDM)
 Fulvia Ronchi (Project Manager) (FR)

In attendance:

NICE Staff:		
NICE attendee 1	Sue Latchem (SL), arrived at 14.40	

Observers:

--	--	--

Notes

1. MS welcomed the group to the 7th meeting of this GDG. Apologies were received from Nick Girdler (Professor of Sedation Dentistry) (NG), Liz McArthur (Lead Clinical Nurse Specialist) (LM), Madeleine Wang (Patient/Carer Representative) (MWg), Sarah Davis (Health Economist Lead) (SD). The Chair asked all GDG members to declare any relevant conflicts of interest. All declared that they knew of no personal specific, personal non-specific, non-personal specific or non-personal non-specific interest in the development of this guideline.
2. The minutes of the last meeting of this group were agreed as a true and accurate account of the meeting.
3. An update was then given to the GDG on progress since the last meeting.

Notes

- 4 The Chair introduced the research fellow Nahara Martinez, who gave presentation on the evidence of efficacy and safety for Midazolam.

The Chair thanked NM for her presentation. The GDG then discussed the clinical interpretation of evidence for Midazolam.
- 5 The Chair introduced the research fellow Kathy De Mott, who gave presentation on the evidence of efficacy and safety for Ketamine.

The Chair thanked KDM for her presentation. The GDG then discussed the clinical interpretation of evidence for Ketamine.
- 6 The Chair introduced the research fellow Kathy De Mott, who gave presentation on the evidence of efficacy and safety for Nitrous oxide.

The Chair thanked KDM for her presentation. The GDG then discussed the clinical interpretation of evidence for Nitrous oxide.
- 7 FR presented the work-plan for the next GDG meeting. Evidence for other four drugs will be presented by the technical team: Opioids (IV morphine; IV fentanyl; IN diamorphine), Propofol, Chloral hydrate, Triclofis sodium. The GDG will discuss the clinical interpretation of evidence for the above drugs.
- 8 MS closed the meeting and thanked everyone for attending.

Date, time and venue of the next meeting

28 September 2009 (Time: 10:00 – 16:00) at NCGC, 4th Floor, c/o Regus (3rd Floor), 338 Euston Rd, London NW1 3BT